Reuters -- Bayer (BAYGn.DE) and J&J JNJ.NO are training their sights on a more than $10 billion drug market as their anti-blood-clotting pill was shown to be a safe alternative to unwieldy warfarin pills in long-term use.
Reuters -- Bayer (BAYGn.DE) and J&J JNJ.NO are training their sights on a more than $10 billion drug market as their anti-blood-clotting pill was shown to be a safe alternative to unwieldy warfarin pills in long-term use.
